Antibacterial oral rinse formulation for preventing coronary artery disease

• US 8,496,914 B2
• Filed: 12/13/2006
• Issued: 07/30/2013
• Est. Priority Date: 12/13/2005
• Status: Active Grant

• Current Assignee: Richard Paul Bonfiglio
• Original Assignee: Richard Paul Bonfiglio
• Inventors: Bonfiglio, Richard Paul
• Primary Examiner(s): Roberts, Lezah
• Application Number:
  US11/638,681
• Publication Number:
  US 20070154414A1
• Time in Patent Office: 2,421 Days
• Field of Search: 424/49, 424/58, 514/729, 514/736, 514/747, 514/901
• US Class Current: 424/49
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 36/328 Commiphora, e.g. mecca myrrh or balm of Gilead
• CPC Class Codes: A61K 36/53 Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• CPC Class Codes: A61K 36/534 Mentha (mint)
• CPC Class Codes: A61K 36/61 Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• CPC Class Codes: A61K 36/752 Citrus, e.g. lime, orange or lemon

Abstract

The present invention provides an antibacterial oral rinse formulation having enhanced antibacterial activity against oral bacteria associated with infectious and inflammatory processes for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting the transient bacteremia associated with oral hygiene activities by the individual. Also provided is a method for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting transient bacteremia associated with oral hygiene activities by the individual, comprising rinsing with the antibacterial oral rinse formulation for a period of time immediately prior to engaging in oral hygiene activities.

Claims

1. An antibacterial oral rinse formulation for inhibiting transient bacteremia associated with causing inflammatory diseases or inflammatory processes associated with diseases as a result of oral hygiene activities in an individual, consisting essentially of the following compounds from tea tree oil:

75% v/v terpinen-4-ol, 2% v/v 1,8-cineole, 2% v/v alpha-terpineol, 5% v/v beta-pinene, 2% v/v p-cymene, 2% v/v limonene, 2% v/v aromadendrene, and 2% v/v terpinolene, in which the total amount of the compounds from tea tree oil in the formulation is 3% v/v;

the following compounds from green tea extract in equal amounts;

gallocatechin, epigallocatechin, epicatechin, and epigallocatechin gallate, in which the total amount of the compounds in the green tea extract in the formulation is 20% v/v;

Menthas arvensis, in which the total amount of the Menthas arvensis in the formulation is 1 % v/v;

chlorophyll;

calcium sorbate;

polysorbate 80;

glycerin;

sodium biphosphate; and

water, wherein the antibacterial oral rinse formulation is contacted with an individual'"'"'s oral cavity for a period of time immediately prior to said oral hygiene activity.

2. The antibacterial oral rinse formulation of claim 1, wherein the antibacterial oral rinse formulation is contacted with an individual'"'"'s oral cavity for a period of time ranging from between about 1 second to about 5 minutes immediately prior to said oral hygiene activity.

3. The antibacterial oral rinse formulation of claim 1, wherein the antibacterial oral rinse formulation is contacted with an individual'"'"'s oral cavity for a period of time ranging from between about 10 seconds to about 3 minutes immediately prior to said oral hygiene activity.

4. The antibacterial oral rinse formulation of claim 1, wherein the antibacterial oral rinse formulation is contacted with an individual'"'"'s oral cavity for a period of time ranging from between about 30 seconds to 60 seconds immediately prior to said oral hygiene activity.

5. The antibacterial oral rinse formulation of claim 1, wherein said contact comprises rinsing the inside of the mouth with between about 0.1 liquid ounce to about 10.0 liquid ounces of the antibacterial oral rinse formulation.

6. The antibacterial oral rinse formulation of claim 1, wherein said contact comprises rinsing the inside of the mouth with about 1.0 liquid ounce of the antibacterial oral rinse formulation.

7. The antibacterial oral rinse formulation of claim 1, wherein said oral hygiene activities are selected from the group consisting of tooth brushing and tooth flossing.

8. The antibacterial oral rinse formulation of claim 1, wherein said inflammatory diseases or inflammatory processes associated with diseases are selected from the group consisting of atherosclerotic plaque formation in coronary arteries, rheumatoid arthritis, lupus erythematosus and related disorders, osteoarthritis, inflammatory bowel disease, thyroiditis, chronic obstructive pulmonary disease, pericarditis, asthma, chronic fatigue syndrome, gout, kawasaki'"'"'s disease, lymphadenopathy, polymyalgia rheumatica, psoriasis, raynaud'"'"'s phenomenon, sarcoidosis, sjogren'"'"'s syndrome, spondyloarthropathies and vasculitides.

9. The antibacterial oral rinse formulation of claim 8, wherein the inflammatory process associated with disease is atherosclerotic plaque formation in coronary arteries.

10. A method for inhibiting transient bacteremia associated with causing inflammatory diseases or inflammatory processes associated with diseases as a result of oral hygiene activities in an individual, comprising rinsing with the antibacterial oral rinse formulation of claim 1 for a period of time immediately prior to engaging in said oral hygiene activities.

11. A method for inhibiting bacterial growth on an oral hygiene device, comprising storing the oral hygiene device in the antibacterial oral rinse formulation of claim 1 between usage of the oral hygiene device.

12. The method according to claim 11, wherein the oral hygiene device is selected from the group consisting of manual toothbrushes, electrically-operated toothbrushes and dental floss.

13. The antibacterial oral rinse formulation of claim 8, wherein the oral rinse formulation further consists essentially of sweeteners selected from the group consisting of sorbitol, mannitol, aspartame, isomalt, saccharin, sucralose, alitame, maltitol, lactitol, xylitol and erythritol.